Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

This study is testing a chemotherapy combination called VIM (vinorelbine, ifosfamide, mesna) combined with VIT (an additional drug regimen) for children and young adults with soft tissue sarcomas (a type of cancer in muscles, tendons, or connective tissue) that have come back or stopped responding to prior treatment. **You may be eligible if...** - You are between 2 and 21 years old - You have been diagnosed with soft tissue sarcoma confirmed by biopsy - Your cancer has relapsed, is refractory (not responding), or has progressed after prior treatment - For rhabdomyosarcoma: you have had 1 to 3 prior lines of treatment - You have at least one measurable tumor that has not been locally treated - Your heart function is adequate (ejection fraction at least 50%) - Your physical performance score is at least 70 out of 100 **You may NOT be eligible if...** - You have fully recovered from chemotherapy toxicity from a recent treatment - You have significant heart rhythm problems or heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.